Introduction
The impact and additional burden of psychiatric disorders in patients with epilepsy, as in other chronic medical conditions, is substantial, involving functioning, 1 quality of life, 2 health costs, mortality 3 and adherence to medical treatment. 4 Behavioral disorders often overshadow seizures and can be the greatest cause of impaired quality of life. It is widely accepted that mood disorders in epilepsy are often undetected and undertreated, however, the majority of studies focused on major depression with information about bipolar disorder (BD) being still limited. In the older literature, it was often stated that BD was rare in epilepsy. 5 Such statements were made prior to the use of standardized diagnostic manuals such as the DSM-IV, and were based upon clinical impressions rather than on a systematic assessment with standardized interviews. It was accepted, however, that affective symptoms, especially in the context of a post-ictal state, might present with manic-like features, although, more generally, the presentation is one of a mixed affective state often with psychotic symptoms. Recent studies pointed out that manic or hypomanic post-ictal symptoms are note rare in epilepsy and have distinguishing features. [6] [7] [8] A large U.S. survey revealed that 12.2% of the epilepsy patients screened positively for bipolar symptoms, which was twice as common as in people with asthma, and seven times as common as in the healthy comparison group. Of those who, in the screening process, were rated as potential bipolar patients, nearly 50% were rated by a physician as having a BD. 8 These data raised some doubts about previous suggestions that bipolarity is rare in people with epilepsy, and raised doubts as to our knowledge of the association between these two disorders. In a recent study, we pointed out that bipolar symptoms frequently occur among patients with epilepsy, although, in the majority of cases, these symptoms are related to phenotype copies of BD, such as the interictal dysphoric disorder, post-ictal manic or hypomanic states and pre-ictal dysphoria. 9 Nevertheless, it has to be acknowledged that, although manic/hypomanic symptoms (MHS) related to BD in the strict sense differ considerably, all MHS need to be recognized in studies of this area because the possible consequences can be profound regardless the specific etiology, especially when the duration and the severity of such symptoms are sufficient to warrant a diagnosis of manic episode according to DSM-IV criteria. In fact, severe manic or mixed episodes, especially if psychotic features are present, may have deleterious effects on social functioning and quality of life (QoL) of patients with epilepsy regardless if they are post-ictal phenomena, part of an interictal dysphoric disorder or due to a true manic-depressive illness. Therefore, in this study, we sought to investigate the association between MHS and social and health-related QOL measures in patients with epilepsy.
Methods
Data were drawn from a collaborative study performed in patients with epilepsy, aimed at investigating clinical and psychopathological features of mood disorders in epilepsy. Patients were recruited in two tertiary referral centers in Europe, namely the Department of Neurology, Amedeo Avogadro University in Novara, Italy and the Department of Neurology, Universitä tsmedizin-Charité , Berlin, Germany. To be enrolled, patients had to fulfill the following criteria: (1) diagnosis of epilepsy according to the ILAE criteria 10 ; (2) age more than 18; (3) absence of learning disabilities, a reading level more than 6th grade and/or a MMSE > 24; (4) absence of severe medical illnesses or a high risk of suicide; (5) be willing to provide a written informed consent to undergo the experimental procedures.
Subjects were assessed using the Mini International Neuropsychiatric Interview (M.I.N.I.) Plus version 5.0.0, a validated DSMbased structured interview for psychiatric disorders 11 and the Quality of Life in Epilepsy 31 Patient Inventory (QOLIE-31). 12 The M.I.N.I. Plus 5.0.0 was developed from the M.I.N.I. 11 as an efficient diagnostic interview, to be used in clinical as well as research settings, and follows DSM-IV and ICD-10 criteria, screening for a number of Axis I diagnoses with brief suicidality and antisocial personality modules. It has been validated in the United States and Europe and is available in several languages. This standardized interview was used to identify patients who presented MHS long and severe enough to meet DSM-IV criteria for manic/hypomanic episodes. Demographic and social variables (age, gender, marital status, educational achievements, employment status, independent living), clinical features (age at onset and duration of the epilepsy, seizure type and syndrome according to ILAE criteria, seizure frequency, antiepileptic drug regime and combinations, MRI features, EEG features and localization), psychopathological characteristics (previous psychiatric history, history of suicide attempts, history of abuse of illicit drugs) and health-related QOL measures (total and subscales scores of QOLIE-31) were investigated in patients with MHS as compared to those without. The frequency of categorical variables was compared between-groups using the x 2 analysis or Fisher's exact test. Continuous demographic and clinical variables were compared using the MannWhitney test. The alpha error was set at 0.05. All statistical analyses were 2-sided and conducted using the Statistical Package for Social Sciences (Version 12 for Windows, SPSS Inc., Chicago, IL).
Results
We analyzed data of 117 patients with epilepsy (51 M, 66 F), age (AES.D.) 43.2 years (AE12.2), age of onset of epilepsy (AES.D.) 27.3 years (AE20.2). There was no between-groups difference in the two centers (Berlin and Novara) in terms of age, gender, duration of the disease, marital status, education level, employment, distribution of epilepsy diagnoses, pattern and frequency of seizures.
A total of 17 patients (13 females) presented MHS that meet DSM-IV criteria for manic/hypomanic episodes. Demographic and social variables (age, gender, marital status, educational achievements, employment status, independent living) and clinical features (age at onset of the epilepsy, epilepsy syndrome, seizure type and frequency, MRI and EEG features or laterality) were not different in these patients as compared to those without (Table 1) . Antiepileptic drug therapy was not different in the two groups; in particular 42.7% were taking carbamazepine, 25.6% valproate, 17.9% lamotrigine, 15.4% levetiracetam, 10.3% barbiturates, 8.5% Table 1 Demographic and clinical variables in patients with epilepsy with and without manic/hypomanic symptoms (MHS).
E-MHS (n = 17)
E-noMHS (n = 100) Previous psychiatric history, presence of lifetime comorbid anxiety disorders, history of suicide attempts or abuse of illicit drugs were not different in the two groups ( Table 2) . QOLIE-31 measures showed that patients with MHS have low scores in emotional well-being (40.3 AE 10.4 vs. 47.5 AE 9.7, p = 0.008), energy and fatigue (42.5 AE 9.0 vs. 48.2 AE 9.5, p = 0.039), medication effects (43.5 AE 9.3 vs. 51.2 AE 9.0, p = 0.004), social function (43.2 AE 10.7 vs. 51.3 AE 10.0, p = 0.005) and total QOLIE score (42.2 AE 12.4 vs. 49.8 AE 11.1, p = 0.026) ( Table 3 ).
Discussion
To the best of our knowledge, this is the first study demonstrating an association between MHS and social and health-related QOL measures in patients with epilepsy, being the majority of studies focused on depression and anxiety. 13, 14 Among different QoL domains, as assessed with the QOLIE-31, associations with total QoL, emotional well-being, energy and fatigue, and social function scores were expected. However, it is interesting to note that social indicators of well-being such as social achievements, independent living or the employment status were not different in patients with MHS as well as the suicide rate and the abuse of illicit drugs ( Table 2 ). All these findings would be in keeping with the observation that MHS in patients with epilepsy might be attributed to clinical entities other than a true psychiatric illness such as BD, and could be seizure-based phenomena (e.g. pre-ictal dysphoria, peri-ictal excitement and so on). 9 Nevertheless, it has also to be considered that a number of publications, mainly in the psychiatric literature, are supporting the view that depressive symptoms rather than MHS are the primary determinants of QoL. 15 Further studies on this issue are needed.
The observed association between MHS and ''adverse effects'' scores represents an interesting point deserving special attention especially because not associated to low ''cognitive functioning'' scores (Table 3) . A recent study pointed out that the subjective perception of cognitive side effects of antiepileptic medications is related more to depressive symptoms than the objective performance. 16 Our results suggest that, on the contrary, MHS may be associated with other aspects such as worries about mental and physical long term effects of drugs. This issue is of relevance because such worries may considerably affect treatment compliance. It is well known, from the psychiatric literature, that bipolarity is associated with poor medication adherence, being reported in half of patients due to dysfunctional thinking and behavior references. 17 Our results put forward the need of further research in this area to clarify whether patients with epilepsy and MHS, independently from their origin, may require specific psychosocial strategies and management approaches from professionals for antiepileptic drug adherence. Limitations of our study should be noted. First, the small sample size has limited the possibility of further analysis differentiating between seizure-based MHS and true psychiatric symptoms. Second, our results may not be representative for epilepsy patients in general because our patients represent a highly selected sample coming from tertiary referral centers.
Conclusions
In conclusion, MHS are associated with poor QoL measures in patients with epilepsy, though without associations with educational achievements, employment status and independent living. This may be in part due to the specific etiology of MHS that seem to be seizure-related behavioral manifestations. Further research in unselected samples of patients with epilepsy differentiating between true bipolar symptoms and seizure-based phenomena are needed to estimate their association with QoL measures. 
